- Home
- LSTA vs RNXT Comparison
LSTA vs RNXT Comparison
Compare LSTA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | RNXT |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 37.0M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSTA | RNXT |
|---|---|---|
| Price | $5.01 | $0.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $8.00 |
| AVG Volume (30 Days) | 53.2K | ★ 478.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | $1,123,000.00 |
| Revenue This Year | N/A | $2,995.35 |
| Revenue Next Year | N/A | $219.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 56.90 | ★ 2511.63 |
| 52 Week Low | $1.81 | $0.70 |
| 52 Week High | $5.07 | $1.45 |
Technical Indicators
Market Signals| Indicator | LSTA | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 49.45 |
| Support Level | $5.00 | $0.81 |
| Resistance Level | $5.07 | $1.07 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 40.00 | 31.91 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.